Cure51 Supercharges Genomic Data Processing with NVIDIA GPUs

Cure51, a Paris-based Techbio company decoding the biology of cancer “Outliers” – patients who beat aggressive cancers – has significantly accelerated its genomic data analysis by integrating NVIDIA’s cutting-edge GPU computing. Benchmarking with NVIDIA H100 GPUs and Parabricks tools delivered a 17x speed boost and halved processing costs compared to traditional CPU workflows.

This leap is critical to Cure51’s Rosalind Study, launched in 2023, which aims to build the world’s largest dataset of cancer super-responders. With Whole Exome Sequencing (WES) at its core, read alignment was a key bottleneck – until now. GPU acceleration allows Cure51 to process data from thousands of samples efficiently, preserving quality while cutting time-to-insight.

By adopting Parabricks, Cure51 seamlessly scaled its platform across genomic data types without restructuring its architecture. This enables faster hypothesis testing and target discovery, accelerating the journey to novel cancer therapies.

CEO Nicolas Wolikow called the NVIDIA integration “a paradigm shift,” enabling Cure51 to manage complex data at scale. Additional optimisations using the full Parabricks toolkit are underway, supporting Cure51’s mission to transform cancer research through advanced computation.